Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program PR Newswire WALTHAM, Mass., Dec. 10, 2024 -- SIGNAL-AA demonstrated encouraging...
Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass., Nov. 7, 2024 -- Bempikibart Phase 2 topline results in atopic dermatitis (AD) and...
Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass., Nov. 5, 2024 WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.29 | 8.84146341463 | 3.28 | 3.58 | 3.26 | 144798 | 3.44628755 | CS |
4 | 0.25 | 7.53012048193 | 3.32 | 4.1499 | 2.99 | 296110 | 3.44161362 | CS |
12 | -43.43 | -92.4042553191 | 47 | 51.2569 | 2.99 | 391904 | 8.418146 | CS |
26 | -32.64 | -90.1408450704 | 36.21 | 53.79 | 2.99 | 230899 | 17.13490783 | CS |
52 | -12.67 | -78.0172413793 | 16.24 | 53.79 | 2.99 | 161898 | 18.31477531 | CS |
156 | -12.67 | -78.0172413793 | 16.24 | 53.79 | 2.99 | 161898 | 18.31477531 | CS |
260 | -12.67 | -78.0172413793 | 16.24 | 53.79 | 2.99 | 161898 | 18.31477531 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約